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Clinicians faced with an HIV-infected patient reporting progressive dyspnoea and 
chronic cough may be familiar with the management of common infectious 
complications of HIV infection such as Pneumocystis jirovecii pneumonia (PCP) and 
bacterial pneumonia. However, since the advent of combination antiretroviral therapy 
(cART) there has been a marked reduction in the incidence of these infectious 
complications (Heffernan et al, 2005, Grubb et al, 2006). In the HIV–uninfected 
population, chronic obstructive pulmonary disease (COPD) is a leading cause of 
mortality and morbidity in the developed world and its economic burden is increasing 
(Lopez et al, 2006, Mathers and Loncar 2006). There are around 900,000 people 
currently diagnosed with COPD in the UK and an estimated 2,200,000 people with COPD 
who remain undiagnosed. This is the equivalent to 13% of the population of England 
aged 35 and over (Shahab et al, 2006). With the improved survival seen since cART, 
COPD is emerging as a significant problem in stable HIV disease and this article 
describes the epidemiology, pathogenesis, clinical presentation and management of 
HIV-infected patients with COPD. 
 
Chronic obstructive pulmonary disease is defined as an irreversible airflow limitation, 
which is usually progressive and associated with an exaggerated chronic inflammatory 
response to noxious particles in the airways or lung (Vestbo et al, 2013). The chronic 
airflow limitation that occurs in COPD is caused by a combination of small airways 
disease (obstructive bronchiolitis) and parenchymal destruction (emphysema). The 
disease course is characterised by frequent exacerbations of symptoms, which have also 
been shown to contribute to an accelerated decline in lung function.  
 
Spirometry is the most widely available and reproducible test of lung function and can 
demonstrate evidence of airflow obstruction required to diagnose COPD. Forced 
expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) are measured and 
a post-bronchodilator FEV1/FVC ratio of <0.70 confirms airflow obstruction. In those 
with evidence of irreversible airways obstruction with an FEV1/FVC of <0.70, the 
predicted FEV1 can be used to give an estimation of disease severity (Vestbo et al, 
2013). With progressive destruction of lung parenchyma, gas exchange, as measured by 
diffusion capacity of the lung for carbon monoxide (also known as transfer factor), is 
impaired and is a manifestation of emphysema. Small airways collapse can be measured 
by assessing the speed of air leaving the lung during the middle portion of a forced 
expiration, called forced expiratory flow (FEF) 25-75%. Gas trapping on expiration, can 






Respiratory symptoms such as cough and dyspnoea were commonly reported among 
HIV-infected patients early in the epidemic.  The high prevalence was attributed to 
pulmonary infection, HIV related inflammation and high rates of cigarette smoking. 
Early studies of pulmonary function revealed transfer factor (TLCO) declined with 
progression of HIV disease in keeping with this hypothesis. In the early 1990’s, pre-
cART, a case series (Diaz et al, 1992) reported emphysematous changes on CT imaging 
and abnormal lung function testing in four individuals (aged <55 years) in the absence 
of pulmonary infection with limited smoking history. The same group performed a 
subsequent case controlled study of 114 HIV-infected individuals without pulmonary 
infections matched for age and smoking with 44 HIV-uninfected controls. This showed 
the presence of emphysema in 15% compared with 2% in the non-HIV infected group 
(Diaz et al, 2000). Abnormalities in diffusion capacity have also been noted in the cART 
era.  A recent cross-sectional analysis of 300 HIV-infected men and 289 HIV-uninfected 
men enrolled from 2009 to 2011 in the Lung HIV Study at several study sites in the US 
showed that, despite most participants having normal airflow, there was a significant 
reduction in TLCO in HIV infected compared with HIV-uninfected men (mean predicted 
69% vs 76%). A moderate to severe reduction of TLCO (≤60%) was observed in 30% of 
HIV-infected compared with 18% of HIV-uninfected men, despite the fact that 89% of 
those with HIV were on cART. A reduced TLCO was significantly associated with being 
HIV infected and with lower CD4 cell count (<200 cells/μl), after adjusting for smoking 
and other confounders. Respiratory symptoms of cough, sputum and dyspnea were 
more prevalent in HIV-infected patients, particularly those with abnormal pulmonary 
function compared with HIV-uninfected patients (Crothers et al, 2013).  
 
In the post-cART era, a prospective observational study from the US of 1,014 HIV-
infected and 713 HIV-uninfected men from the Veterans Aging Cohort Study (VACS) 
assessed prevalence of COPD as determined by International Classification of Diseases, 
ninth revision (ICD-9). After adjusting for age, race/ethnicity, pack-years of cigarette 
smoking, IVDU, and alcohol misuse, HIV infection was an independent risk factor, with 
COPD 50-60% more likely in those with HIV (Crothers et al, 2006). This finding was 
confirmed in a larger follow up study of the same cohort (Crothers et al, 2011).  There 
are now several studies from North America and one from Europe have assessed the 
prevalence and risk factors obstructive airways disease in HIV-infected individuals. A 
comprehensive list of these studies and the key findings are shown in table 1. Data from 
Brighton, UK has shown 15% prevalence of airflow obstruction (FEV1:FVC <0.7) post-
bronchodilator in 133 consecutive patients recruited from an HIV outpatient clinic 




The respiratory tract serves as an interface between the host and the environment; 
pulmonary immune defences encompass both innate and acquired responses. 
Pathogens entering the respiratory tract are phagocytosed by alveolar macrophages, 
the main component of the innate immune system in the lung. Alveolar macrophages 
are generally immunosuppressive to prevent an inflammatory response. If the innate 
host defence is impaired, persistence of the antigen stimulates specific acquired 
immune responses. This occurs in the lymphoid tissue of the lung and results in 
production of antigen specific T and B cells; under the control of local chemokine 
production, these migrate to the sites of the initial challenge. Studies have demonstrated 
the accumulation of CD8+ T-cells in the lungs of patients with severe COPD; HIV positive 
smokers have also been shown to have a higher percentage of CD8+ T cells detectable 
on bronchoalveolar lavage. HIV infection causes activation of alveolar macrophages, a 
reduction in CD4 T-cell count, increased number and percentage of CD8 T-cells and an 
increased CD4:CD8 ratio in the alveolar space with generalized CD4 and CD8 T-cell 
activation (Beck J, 2013, Twigg H and Knox S, 2013). This leads to a cycle of pulmonary 
inflammation and damage. 
 
Role of Pneumocystis jirovecii colonisation 
 
The lung microbiome is a rapidly expanding area of research and studies have shown 
wide variability in the microbiological population in the lungs of HIV-infected as 
compared with uninfected individuals (Ireland et al, 2012, Twigg et al, 2010 and 2011). 
 
Pneumocystis jirovecii is a well-recognised cause of pneumonia (PCP) in those with HIV 
infection. In HIV-uninfected individuals, colonisation with P. jirovecii is a risk factor for 
COPD severity, independent of smoking history or corticosteroid use. In HIV-infected 
patients the frequency of P. jirovecii colonisation has been reported as 40-58%. While 
those with lower CD4 counts appear to have increased rates of colonisation, other 
studies have suggested that this still occurs in those on antiretroviral therapy, with 
higher CD4 counts and in those taking PCP prophylaxis (Morris and Norris, 2012).  
 
A study of HIV-infected individuals showed worse airflow obstruction in those 
colonized with P. jirovecii, even adjusting for smoking history. Animal studies also 
suggest colonisation with pneumocystis may play a role in the development of COPD. 
One study in primates revealed macaques infected with simian immunodeficiency virus 
(SIV) developed pneumocystis colonisation and these animals had higher rates of airflow 
obstruction and increased emphysematous changes. Immunocompetent mice colonised 
by pneumocystis and exposed to cigarette smoke were more likely to develop 
emphysema than non-colonized mice or those not exposed to cigarette smoke, implying 
these two factors are synergistic (Morris and Norris, 2012). 
 
The inflammatory response to pneumocystis in the lung is similar to that seen in COPD, 
even when P. jirovecii is detected at low levels, as occurs in colonisation. These changes 
include increased numbers of CD8 lymphocytes, neutrophils and macrophages. It 
remains to be determined if colonisation with pneumocystis in those with COPD is a 
cause of ongoing inflammation or a marker of structural lung damage and use of 




A diagnosis of COPD should be considered in any HIV-infected patient who reports 
dyspnoea, chronic cough or sputum production, particularly in those with a history of 
exposure to a risk factor such as cigarette smoke, occupational exposure to dust and 
chemicals, irrespective of the CD4 count and whether or not the patient is taking cART.  
Chronic cough is often the first symptom of COPD to develop, the cough may be dry, but 
commonly patients with COPD produce small amounts of sputum. Large volume sputum 
production should raise the suspicion of underlying bronchiectasis.  
Dyspnoea is another common symptom in individuals with COPD and frequently 
encountered in HIV-infected persons with a wide differential diagnosis. In the early 
stages dyspnoea may be reported on exertion but as lung function deteriorates 
increasing breathlessness may occur at rest and cause significant disability and anxiety. 
PCP should always be considered in those who are not receiving cART and who have 
low CD4 counts (<250 cells/μl). Wheezing and chest tightness are nonspecific 
symptoms that may also be present, usually after exertion, however their absence does 
not exclude COPD.  
 
The differential diagnosis for HIV infected patients with chronic cough and dyspnoea is 
shown in Table 2.  
It is important to assess for other features of severe COPD such as ankle swelling which 
may suggest the development of right heart failure from cor pulmonale. Careful 
attention should also be paid to detecting anxiety or depression, which are associated 
with worse outcomes and more frequent in individuals with HIV (Rabkin, 2008). Weight 





In those with chronic cough and shortness of breath chest radiography should be a first 
line investigation. It is useful to exclude other causes such as malignancy or 
tuberculosis, and during exacerbations to exclude complications of COPD such as 
pneumonia and pneumothorax. In COPD the chest radiograph may show 
hyperexpanded lung fields (>7th anterior rib intersecting the diaphragm at the mid-
clavicular line), flattening of the hemidiaphragms, and if bullous lung disease is present 
this may be seen as a hyperlucency in lung fields (Figure 1). 
 
 
Figure 1. Radiograph of 50-year-old male ex-smoker, diagnosed with HIV 1998. 
Recurrent pneumonia. Started cART 2006, current CD4 300 cells/μl, VL <50 copies/ml 
 
Computed tomography (CT) chest 
 
In the late 1980s a high prevalence of bullous lung disease was noted on CT scans of 
HIV-infected individuals and occurring at a younger age (mean 37 years) compared to 
other immunocompromised individuals (Kuhlman et al, 1989). Features of COPD seen 
on chest CT include: prominent small airways, emphysema which can be centriacinar, 
panacinar and para-septal and mosaic attenuation due to gas trapping from obstructive 
bronchiolitis. Expiratory phase high resolution CT scan can show evidence of air-
trapping, which in some patients may be the only sign of an early-stage small airways 
disease in an otherwise normal lung. More severe disease is characterized by the 
development of thin walled bullae. (Figure 2).  
 
 
Figure 2. CT chest of 44 year old male, current smoker. HIV diagnosed 2004 with PCP 
infection. Started cART 2009 poor compliance, CD4 170 cells/μl, VL >100,000 copies/ml 
 
Important considerations when managing HIV-infected patients with COPD  
 
Pharmacotherapy and drug-drug interactions 
 
In the absence of data specific to the HIV population pharmacotherapy for COPD is in 
line with guidelines for the HIV-uninfected population. Inhaled bronchodilators (B2 
agonists and anticholinergics) are the preferred initial therapy with inhaled 
corticosteroids reserved for those with severe disease.  
 
There are several important interactions for prescribers to be aware:  
 
 Inhaled corticosteroids. Multiple case reports describe iatrogenic Cushing’s 
syndrome in individuals on ritonavir-boosted protease inhibitor antiretroviral 
regimen treated with fluticasone (a component of Seretide®) due to reduced 
steroid metabolism (Foisy et al, 2008). Ritonavir is a potent inhibitor of the 
hepatic CYP3A4 isoenzyme. Other inhaled steroids metabolised by this route 
include budesonide and mometasone; beclomethasone is not and can be safely 
administered with ritonavir containing antiretroviral therapy. Of note, the new 
pharmacoenhancer cobicistat, currently only available as part of a fixed dose 
combination called Stribild®, is also a potent CYP3A4 inhibitor and therefore 
should not be administered with inhaled steroids other than beclomethasone. 
Inhaled corticosteroids should be used with caution in HIV-infected individuals 
as these are known to increase risk of bacterial pneumonia (Calverley et al, 
2007) and this risk remains elevated despite the use of cART (Heffernan et al, 
2005).  
 
 Long acting beta-agonists. Co-administration of salmeterol (also contained in 
Seretide®) with ritonavir is not recommended due to increased salmeterol 
concentrations that may result in QT prolongation, palpitations and sinus 
tachycardia (Norvir SPC 2012).  
 
 Short and long acting anticholinergics are thought to be safe with cART 
although this interaction has not been studied.  
 
 Oral prednisolone is frequently used in short courses to treat COPD 
exacerbations. A study of co-administration of prednisolone 20mg once daily 
with ritonavir 200mg twice daily (a higher dose than used in clinical practice) 
showed an increased area under the curve of the active metabolite prednisolone 
by 37% and 28% after 4 and 14 days of ritonavir, respectively (Norvir SPC 
2012). This is unlikely to be of clinical significance in short courses but 
monitoring for therapeutic and adverse effects is advised with prolonged 
courses. 
 
Role of antiretroviral therapy 
 
Due to the early onset of COPD in HIV, surrogate markers have been investigated; the 
most studied factor is the impact of HIV viral load. Poorly controlled HIV has been 
associated with worse lung function; the afore-mentioned VACS cohort study described 
earlier showed COPD was less likely in those with suppressed HIV RNA levels (<400 
copies/ml) and those on cART at baseline (Crothers et al, 2011). Another study of 1077 
former injection drug users demonstrated that airway obstruction was associated with 
HIV viral loads >200,000 copies/ml. In a longitudinal study follow up of this cohort over 
median 2.75 years, high HIV viral load (>75,000 copies/ml) and low CD4 count (<100 
cells/μl) were associated with reduced FEV1 and FVC (Drummond et al, 2013).  
With the initiation of cART there is a trend to normalisation of pulmonary immune 
function. Despite this, two studies have suggested worse airflow obstruction in patients 
on cART (George et al, 2009, Gingo et al, 2010). Possible explanations for this 
observation might be the timing of cART in different populations or immune response 
to subclinical infections.  
 




The prevalence of cigarette smoking among HIV-infected individuals ranges from 44-
86% depending on the population studied. Smoking cessation in the non-HIV 
population has been shown to delay decline in lung function (Fletcher and Peto, 1977) 
and should be the main focus of any treatment strategy. Most smoking cessation trials 
use motivational interviewing with or without nicotine replacement therapy. The 
success reported for smoking cessation interventions in individuals with HIV has shown 
variable results. A study of 474 HIV positive smokers, randomised to usual care or 
counselling via mobile phone intervention demonstrated significantly greater 
abstinence up to 3 months; however, the effect diminished after 6 and 12 months (Gritz 
et al, 2013). Another randomised study of 209 HIV positive smokers to nicotine 
replacement combined with counselling, self-help or internet-based treatment all arms 
showed comparable results (Humfleet et al, 2013). The largest study of varenicline 
compared it to nicotine replacement therapy, both with telephone counselling in 228 
HIV positive smokers. This showed promising results with biochemically confirmed 
abstinence rates at three months of 25.6% vs 11.8% respectively.  The adverse event 
profile was similar to the general population and there was no association of adverse 




The combination of COPD and HIV is associated with higher rate of self-reported 
physical disability and decreased physical functioning (Oursler et al, 2011). In HIV-
uninfected individuals with COPD, pulmonary rehabilitation significantly improves 
physical functioning. Systemic effects of inflammation from HIV can contribute to 
reduction in muscle mass and exercise capacity. Aerobic exercise appears to be safe and 
may be beneficial for HIV infected adults but the optimal exercise regime for those with 
HIV and COPD is yet to be determined (Nixon et al, 2010). 
 
Conclusions and future perspectives 
 
COPD is a major cause of morbidity and mortality in the UK. With the ageing HIV 
population and due to the insidious onset of symptoms, physicians managing those with 
HIV should enquire routinely about smoking habits and pay particular attention to 
eliciting symptoms of COPD such as cough, dyspnoea, sputum production and wheezing.  
 
Even after controlling for known risk factors COPD appears to be more prevalent in 
individuals with HIV. This may be related to chronic inflammatory changes that occur as 
well as immune response to subclinical microorganisms colonising the respiratory tract. 
 
The prevalence of cigarette smoking in the HIV-population is extremely high and the 
key focus of any treatment strategy should be smoking cessation. Pharmacotherapy is in 
line with national guidance for management of COPD, but there are significant drug-
drug interactions which patients, General Practioners and Specialists need to be aware 
of (particularly those taking CYP3A4 inhibitors, such as ritonavir and cobicistat). 
Complex patients may benefit from early involvement of a respiratory specialist with an 
interest in HIV.  
 
Novel treatment strategies may look at using anti-inflammatory agents and assessing 
response to eradication of PCP in those who are colonised. Antiretroviral therapy is 
important to prevent pulmonary opportunistic infections and to reverse systemic and 
intrapulmonary inflammation. Given the trend for earlier initiation of cART it will be 





 Physicians caring for HIV infected patients should be alert for COPD 
 
 Even after controlling for cigarette smoking COPD appears to be more prevalent   
   among HIV-infected persons than among the general population 
 
 Treatment is as for general population – i.e. smoking cessation and pharmacologic  
   interventions 
 
 Clinically significant drug–drug interactions  
   www.hiv-druginteractions.org 
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